MyndTec Inc. Completes Additional Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - January 7, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed an additional tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The additional tranche of the private placement, the tenth of the Offering, consists of 618,118 Units of the Company (t
Technologies, Soins de santé et hôpitaux, Santé
2026-01-07 6:00 PM EST | MyndTec Inc.
PhantomOmics Announces Clinical Collaboration with Banff Sport Medicine to Advance Non-Invasive Health Scanning Protocols
Calgary, Alberta--(Newsfile Corp. - January 6, 2026) - PhantomOmics Inc., a Calgary-based health technology company developing non-invasive, AI-powered health scanning systems, today announced a new clinical collaboration with Banff Sport Medicine, one of Canada's leading orthopaedic and sport medicine clinics.
Technologies, Soins de santé et hôpitaux, Capteurs, Santé
2026-01-06 4:27 PM EST | PhantomOmics Inc.
Adia Nutrition Inc. Announces Landmark Autism Spectrum Disorder Clinical Study Now Live on ClinicalTrials.gov
Winter Park, Florida--(Newsfile Corp. - January 5, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine through its subsidiary Adia Med, today announced that its patent-pending clinical study targeting Autism Spectrum Disorder (ASD) has gone live on ClinicalTrials.gov, marking a significant advancement in the company's research pipeline.
Soins de santé et hôpitaux, Santé
2026-01-05 10:21 AM EST | Adia Nutrition Inc.
RELIEF AI's Digital Well-Being Innovation "RELIEF AI - Naia" Recognized as a "Recommended Measure for 2025" by Leading German Health Promotion Organization
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - Relief AI Inc. (the "Company "or "Relief AI") is proud to announce that its groundbreaking digital well-being solution, RELIEF AI - Naia, has been officially recognized as a "Recommended Measure 2025" by the Gesellschaft für Prävention (GpeV), a leading German health promotion organization. This official recognition was granted after a thorough review and evaluation by the GPeV, which cited the exceptional value of
Technologies, Soins de santé et hôpitaux, Santé
2026-01-05 7:00 AM EST | Relief AI Inc.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, announces that it has extended the term of a consulting agreement, as amended, previously announced June 11, 2025 and November 21, 2025, with a third party branding expert to provide strate
Technologies, Soins de santé et hôpitaux, Santé
2025-12-31 6:00 PM EST | FendX Technologies Inc.
HEALWELL AI Provides Additional Information Regarding November 3, 2025, Release Where it Announced Strategic Divestments
Toronto, Ontario--(Newsfile Corp. - December 31, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is issuing this press release at the request of the Ontario Securities Commission, pursuant to an ongoing disclosure review, to provide additional information on certain statements included in its press release dated November 3, 2025 (the "November 3r
Technologies, Soins de santé et hôpitaux
2025-12-31 4:30 PM EST | HEALWELL AI
BioMark: 2025 Achievements & 2026 Vision
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux. Dear BioMark Shareholders and Team, As we reflect on 2025, we celebrate a transformative year that positions B
Technologies, Biotechnologies, Soins de santé et hôpitaux
2025-12-31 8:30 AM EST | BioMark Diagnostics, Inc.
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that Mr. James Lavender has joined the BioMark Board of Directors. His appointment follows resolutions accepted during the Company's Annual General Meeting (AGM) held on December 22nd, 2025. Mr. Lavender and his group we
Technologies, Biotechnologies, Soins de santé et hôpitaux
2025-12-30 8:30 AM EST | BioMark Diagnostics, Inc.
FONAR Signs Definitive Agreement for "Take Private" Sale to Acquisition Group Led by CEO
Melville, New York--(Newsfile Corp. - December 29, 2025) - FONAR Corporation (NASDAQ: FONR) ("FONAR" or the "Company"), The Inventor of MR Scanning™, today confirmed that it entered into a definitive agreement on December 23, 2025 (the "Merger Agreement") with FONAR, LLC and FONAR Acquisition Sub, Inc. (collectively, "Buyer"), under which, subject to the satisfaction of the conditions set forth in the Merger Agreement, Buyer will acquire all of the issued and outstanding shares of the C
Technologies, Soins de santé et hôpitaux
2025-12-29 4:30 PM EST | Fonar Corporation
Adia Nutrition Inc. Recaps Transformative 2025: Explosive Growth, Strategic Focus, and Path to Nasdaq Uplisting
Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced a year-end recap of its pivotal 2025 achievements. The company delivered remarkable financial performance, operational expansion, and strategic milestones, positioning itself for sustained growth and an anticipated Nasdaq uplisting. "2025 has been a defining year of execution and momentum f
Soins de santé et hôpitaux, Santé
2025-12-29 9:00 AM EST | Adia Nutrition Inc.
Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage
Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare
Soins de santé et hôpitaux, Santé
2025-12-24 8:00 AM EST | Obesity Medicine Association
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2025-12-23 4:40 PM EST | Theralase Technologies Inc.
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2025-12-23 8:45 AM EST | Phio Pharmaceuticals Corp.
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that it has officially initiated its ISO 15189 accreditation program with the Standards Council of Canada (SCC) for its medical laboratory in Quebec City. The accreditation process officially commenced on December 19, 2025. BioMark has engaged the Standards
Technologies, Biotechnologies, Soins de santé et hôpitaux
2025-12-23 8:30 AM EST | BioMark Diagnostics, Inc.